[1] HELANTERA I, EGLI A, KOSKINEN P, et al. Viral impact on long-term kidney graft function[J]. Infect Dis Clin North Am, 2010, 24(2):339-371.
[2] HASANZAMANI B, HAMI M, ZOLFAGHARI V, et al. The effect of cytomegalovirus infection on acute rejection in kidney transplanted patients[J]. J Renal Inj Prev, 2016, 5(2):85-88.
[3] SAGEDAL S, HARTMANN A, NORDAL K P, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival[J]. Kidney Int, 2004, 66(1):329-337.
[4] WEIKERT B C, BLUMBERG E A.Viral infection after renal transplantation:surveillance and management[J]. Clin J Am Soc Nephrol, 2008, 3(2):76-86.
[5] YU X, SHAH S, LEE M, et al. Biochemical and structural characterization of the capsid-bound tegument proteins of human cytomegalovirus[J]. J Struct Biol, 2011, 174(3):451-460.
[6] ASBERG A, JARDINE A G, BIGNAMINI A A, et al. Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients[J]. Am J Transplant, 2010, 10(8):1881-1888.
[7] RUBIN R H.The pathogenesis and clinical management of cytomegalovirus infection in the organ transplant recipient:the end of the ‘silo hypothesis’[J]. Curr Opin Infect Dis, 2007, 20(4):399-407.
[8] KIM S H, LEE H J, KIM S M, et al. Diagnostic usefulness of cytomegalovirus(CMV)-specific T cell immunity in predicting CMV infection after kidney transplantation:a pilot proof of concept study[J]. Infect Chemother, 2015, 47(2):105-110.
[9] SAGEDAL S, NORDAL K P, HARTMANN A, et al. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients[J]. Transplantation, 2000, 70(8):1166-1174.
[10] FENG S, YANG J, WANG W, et al. Incidence and risk factors for cytomegalovirus infection in patients with kidney transplantation:a single-center experience[J]. Transplant Proc, 2016, 48(8):2695-2699.
[11] EINOLLAHI B.Cytomegalovirus infection following kidney transplantation:a multicenter study of 3065 cases[J]. Int J Organ Transplant Med, 2012, 3(2):74-78.
[12] 陈强, 王明丽, 施浩强.肾移植后人巨细胞病毒肺炎的诊断与治疗研究进展[J]. 安徽医学, 2017, 38(12):1617-1620.
[13] 马麟麟, 郭宏波, 张玉海.肾移植术后巨细胞病毒间质性肺炎的诊疗经验[J]. 中华器官移植杂志, 1999, 20(4):350.
[14] FRANQUET T, LEE K S, MULLER N L.Thin-section CT findings in 32 immunocompromised patients with cytomegalovirus pneumonia who do not have AIDS[J]. AJR Am J Roentgenol, 2003, 181(4):1059-1063.
[15] 李钢, 石炳毅, 巨春蓉, 等.实体器官移植术后感染诊疗技术规范(2019版)-总论与细菌性肺炎[J]. 器官移植, 2019, 10(4):343-351.
[16] 刘海龙, 邓益森, 应文伟, 等.肾移植术后并发卡氏肺孢子虫肺炎(附4例报告)[J]. 中日友好医院学报, 2019, 33(6):335-337.
[17] 王保贵, 刘静, 袁玉山, 等.新型冠状病毒肺炎CT影像特征及其诊断价值分析[J]. 临床肺科杂志, 2020, 25(9):1317-1320.
[18] BERGALLO M, COSTA C, TERLIZZI M E, et al. Evaluation of two set of primers for detection of immediate early gene UL123 of human cytomegalovirus(HCMV)[J]. Mol Biotechnol, 2008, 38(1):65-70.
[19] BANKIER A T, BECK S, BOHNI R, et al. The DNA sequence of the human cytomegalovirus genome[J]. DNA Seq, 1991, 2(1):1-12.
[20] MEWARA A, MISHRA B, RATHO R K, et al. Comparison of PCRs for IE-1 and gB genes with ELISA of IgM antibodies for diagnosis of human cytomegalovirus disease[J]. Acta Virol, 2010, 54(4):315-316.
[21] ADAIR R, LIEBISCH G W, LERMAN B J, et al. Human cytomegalovirus temporally regulated gene expression in differentiated, immortalized retinal pigment epithelial cells[J]. J Clin Virol, 2006, 35(4):478-484.
[22] 王垒.肾移植术后巨细胞病毒感染的早期诊断[J]. 肾脏病与透析肾移植杂志, 2016, 25(3):286-290.
[23] 陈俊星, 郑克立, 陈立中, 等.肾移植术后巨细胞病毒感染的pp67 mRNA检测及其临床意义[J]. 中华实验外科杂志, 2004, 21(11):1384-1386.
[24] 罗灿峤, 莫木琼, 钟觉民, 等.检测巨细胞病毒(CMV) DNA及其即刻早期抗原pp65和pp67在肾移植受者术后巨细胞病毒感染早期诊断中的价值[J]. 中国组织化学与细胞化学杂志, 2014, 23(4):363-367.
[25] BAALAWI F, ROBERTSON P, RAWLINSON W D.Detection of human cytomegalovirus IgG antibody using automated immunoassay with recombinant antigens gives uniform results to established assays using whole virus antigens[J]. Pathology, 2010, 42(6):578-580.
[26] LEE S, PARK J B, KIM E Y, et al. Monitoring of cytomegalovirus-specific CD8+T-cell response with major histocompatibility complex pentamers in kidney transplant recipients[J]. Transplant Proc, 2011, 43(7):2636-2640.
[27] 赵鹏, 钱冬萌, 宋旭霞.肾移植患者HCMV激发感染与血T淋巴细胞亚群的相关性分析[J]. 世界最新医学信息文摘, 2015, 26:140.
[28] KOTTON C N.Management of cytomegalovirus infection in solid organ transplantation[J]. Nat Rev Nephrol, 2010, 6(12):711-721.
[29] HADAYA K, de RHAM C, BANDELIER C, et al. Natural killer cell receptor repertoire and their ligands, and the risk of CMV infection after kidney transplantation[J]. Am J Transplant, 2008, 8(12):2674-2683.
[30] 白纪民, 李浩, 张晓明, 等.肾移植术后巨细胞病毒感染的危险因素分析和血清甘露聚糖结合凝集素的预测价值[J]. 器官移植, 2013, 4(2):79-83.
[31] RAZONABLE R R, van CRUIJSEN H, BROWN R A, et al. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir[J]. J Infect Dis, 2003, 187(11):1801-1808.
[32] EID A J, RAZONABLE R R.New developments in the management of cytomegalovirus infection after solid organ transplantation[J]. Drugs, 2010, 70(8):965-981.
[33] NANMOKU K, SHINZATO T, KUBO T, et al. Prevention of late-onset cytomegalovirus infection and disease in donor-positive/recipient-negative kidney transplant recipients using low-dose valganciclovir[J]. Transplant Proc, 2018, 50(1):124-129.
[34] MEIJE Y, FORTUN J, LEN O, et al. Prevention strategies for cytomegalovirus disease and long-term outcomes in the high-risk transplant patient(D+/R-):experience from the RESITRA-REIPI cohort[J]. Transpl Infect Dis, 2014, 16(3):387-396.
[35] DEVRESSE A, LERUEZ-VILLE M, SCEMLA A, et al. Reduction in late onset cytomegalovirus primary disease after discontinuation of antiviral prophylaxis in kidney transplant recipients treated with de novo everolimus[J]. Transpl Infect Dis, 2018, 20(2):e12846. |
